Brolis Semiconductors — Deal Deep Dive

Company Overview

Brolis Semiconductors is a Vilnius-based deep-tech photonics company developing mid-infrared (mid-IR) laser diode chips for medical diagnostics, industrial gas sensing, and defence applications. A spin-out from Brolis Group, the company holds proprietary III-V semiconductor fabrication IP — a technically demanding discipline with meaningful barriers to replication. Revenue sits at approximately €3M, placing it firmly in the sub-scale category, though scale is largely irrelevant here: this is an IP and capability story, not a revenue story. EIC Accelerator validation adds institutional credibility and signals the technology has cleared rigorous independent due diligence.

Deal Context

The M&A angle is unambiguous: Brolis is a strategic acquisition target. NATO's accelerating push for sovereign sensor supply chains — particularly across dual-use photonics and defence electronics — creates urgent demand for exactly the kind of vertically integrated, European-domiciled III-V fabrication capability Brolis offers. Likely acquirers include European defence and photonics primes (Leonardo DRS, Thales, Jenoptik, II-VI/Coherent) and US tier-one defence contractors seeking EU-compliant sovereign supply chain optionality. Growth equity from EIC Fund or a deep-tech-focused VC bridge to an exit is also plausible. A trade sale is the dominant exit path; IPO is a distant secondary option given market depth constraints in the Baltics for deep-tech issuers.

Valuation Context

Baltic listed comparables trade at 5.3x–13.2x EV/EBITDA, with a median around 7.6x. These are, however, largely consumer, retail, and industrial businesses — poor proxies for a defence-adjacent IP company. A standard 30–40% private-company illiquidity discount applied to the Baltic median yields a directional EV/EBITDA range of roughly 4.5x–9x, but this framework is largely academic at €3M revenue with uncertain EBITDA margins. More relevant benchmarks are defence-tech and photonics M&A transactions, where acquirers routinely pay 4x–8x revenue for IP-rich, sub-scale targets with sovereign supply chain scarcity value. At 5x–7x revenue, indicative enterprise value lands in the €15M–€21M range — with meaningful upside if a competitive process develops among multiple strategic bidders.

Triage Verdict

VERDICT: GO — approach management and request preliminary data room

• Fit: Dual-use defence/medical positioning is precisely on-trend; EIC validation de-risks technology; Baltic domicile aligns with NATO sovereign sourcing mandates; IP moat is genuine and defensible
• Red flags: Key-man risk is material in a highly specialised III-V fabrication team; customer concentration at this revenue scale is almost certain; commercial ramp from €3M remains unproven and dependent on defence procurement timelines that can slip materially
• Next step: Initiate founder dialogue through Lithuanian Innovation Agency relationship; request customer pipeline breakdown, IP ownership structure confirmation, and EBITDA bridge; assess whether EIC co-investment terms restrict exit optionality

Key Risk

Defence procurement timelines are notoriously unpredictable — a programme delay or shift in NATO member budget priorities could leave Brolis in a prolonged pre-revenue growth phase, burning cash and diluting early investors before a strategic acquirer crystallises value.

Bottom line: Brolis Semiconductors is a rare, credibly IP-protected European mid-IR photonics asset arriving at exactly the right geopolitical moment — the asymmetric risk here is missing it, not overpaying for it.